Weekly nab-paclitaxel in combination with carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: analysis of safety and efficacy in patients with renal impairment.
Identifieur interne : 000228 ( Main/Exploration ); précédent : 000227; suivant : 000229Weekly nab-paclitaxel in combination with carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: analysis of safety and efficacy in patients with renal impairment.
Auteurs : Corey J. Langer [États-Unis] ; Vera Hirsh [Canada] ; Amy Ko [États-Unis] ; Markus F. Renschler [États-Unis] ; Mark A. Socinski [États-Unis]Source :
- Clinical lung cancer [ 1938-0690 ] ; 2015.
Descripteurs français
- KwdFr :
- Adulte, Adulte d'âge moyen, Albumines (administration et posologie), Carboplatine (administration et posologie), Carcinome pulmonaire non à petites cellules (anatomopathologie), Carcinome pulmonaire non à petites cellules (traitement médicamenteux), Femelle, Humains, Insuffisance rénale (), Insuffisance rénale (physiopathologie), Jeune adulte, Mâle, Paclitaxel (administration et posologie), Protocoles de polychimiothérapie antinéoplasique (administration et posologie), Protocoles de polychimiothérapie antinéoplasique (effets indésirables), Protocoles de polychimiothérapie antinéoplasique (usage thérapeutique), Résultat thérapeutique, Sujet âgé, Sujet âgé de 80 ans ou plus, Survie sans rechute, Taux de survie, Tumeurs du poumon (anatomopathologie), Tumeurs du poumon (traitement médicamenteux).
- MESH :
- administration et posologie : Albumines, Carboplatine, Paclitaxel, Protocoles de polychimiothérapie antinéoplasique.
- anatomopathologie : Carcinome pulmonaire non à petites cellules, Tumeurs du poumon.
- effets indésirables : Protocoles de polychimiothérapie antinéoplasique.
- physiopathologie : Insuffisance rénale.
- traitement médicamenteux : Carcinome pulmonaire non à petites cellules, Tumeurs du poumon.
- usage thérapeutique : Protocoles de polychimiothérapie antinéoplasique.
- Adulte, Adulte d'âge moyen, Femelle, Humains, Insuffisance rénale, Jeune adulte, Mâle, Résultat thérapeutique, Sujet âgé, Sujet âgé de 80 ans ou plus, Survie sans rechute, Taux de survie.
English descriptors
- KwdEn :
- Adult, Aged, Aged, 80 and over, Albumins (administration & dosage), Antineoplastic Combined Chemotherapy Protocols (administration & dosage), Antineoplastic Combined Chemotherapy Protocols (adverse effects), Antineoplastic Combined Chemotherapy Protocols (therapeutic use), Carboplatin (administration & dosage), Carcinoma, Non-Small-Cell Lung (drug therapy), Carcinoma, Non-Small-Cell Lung (pathology), Disease-Free Survival, Female, Humans, Lung Neoplasms (drug therapy), Lung Neoplasms (pathology), Male, Middle Aged, Paclitaxel (administration & dosage), Renal Insufficiency (complications), Renal Insufficiency (physiopathology), Survival Rate, Treatment Outcome, Young Adult.
- MESH :
- chemical , administration & dosage : Albumins, Carboplatin, Paclitaxel.
- administration & dosage : Antineoplastic Combined Chemotherapy Protocols.
- adverse effects : Antineoplastic Combined Chemotherapy Protocols.
- complications : Renal Insufficiency.
- drug therapy : Carcinoma, Non-Small-Cell Lung, Lung Neoplasms.
- pathology : Carcinoma, Non-Small-Cell Lung, Lung Neoplasms.
- physiopathology : Renal Insufficiency.
- therapeutic use : Antineoplastic Combined Chemotherapy Protocols.
- Adult, Aged, Aged, 80 and over, Disease-Free Survival, Female, Humans, Male, Middle Aged, Survival Rate, Treatment Outcome, Young Adult.
Abstract
Renal impairment in cancer patients can affect treatment tolerability and outcomes. This analysis evaluated the safety and efficacy of nab-paclitaxel (nab-P) versus solvent-based paclitaxel (sb-P), both in combination with carboplatin (C), in patients with advanced non-small-cell lung cancer (NSCLC) and renal impairment.
DOI: 10.1016/j.cllc.2014.09.003
PubMed: 25572008
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000496
- to stream PubMed, to step Curation: 000496
- to stream PubMed, to step Checkpoint: 000496
- to stream Ncbi, to step Merge: 004684
- to stream Ncbi, to step Curation: 004684
- to stream Ncbi, to step Checkpoint: 004684
- to stream Main, to step Merge: 000228
- to stream Main, to step Curation: 000228
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Weekly nab-paclitaxel in combination with carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: analysis of safety and efficacy in patients with renal impairment.</title><author><name sortKey="Langer, Corey J" sort="Langer, Corey J" uniqKey="Langer C" first="Corey J" last="Langer">Corey J. Langer</name><affiliation wicri:level="2"><nlm:affiliation>University of Pennsylvania, Perelman Center for Advanced Medicine, Abramson Cancer Center, Philadelphia, PA. Electronic address: corey.langer@uphs.upenn.edu.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Pennsylvanie</region></placeName><wicri:cityArea>University of Pennsylvania, Perelman Center for Advanced Medicine, Abramson Cancer Center, Philadelphia</wicri:cityArea></affiliation></author><author><name sortKey="Hirsh, Vera" sort="Hirsh, Vera" uniqKey="Hirsh V" first="Vera" last="Hirsh">Vera Hirsh</name><affiliation wicri:level="4"><nlm:affiliation>McGill University, Montreal, Quebec, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>McGill University, Montreal, Quebec</wicri:regionArea><orgName type="university">Université McGill</orgName><placeName><settlement type="city">Montréal</settlement><region type="state">Québec</region></placeName></affiliation></author><author><name sortKey="Ko, Amy" sort="Ko, Amy" uniqKey="Ko A" first="Amy" last="Ko">Amy Ko</name><affiliation wicri:level="2"><nlm:affiliation>Celgene Corporation, Summit, NJ.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">New Jersey</region></placeName><wicri:cityArea>Celgene Corporation, Summit</wicri:cityArea></affiliation></author><author><name sortKey="Renschler, Markus F" sort="Renschler, Markus F" uniqKey="Renschler M" first="Markus F" last="Renschler">Markus F. Renschler</name><affiliation wicri:level="2"><nlm:affiliation>Celgene Corporation, Summit, NJ.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">New Jersey</region></placeName><wicri:cityArea>Celgene Corporation, Summit</wicri:cityArea></affiliation></author><author><name sortKey="Socinski, Mark A" sort="Socinski, Mark A" uniqKey="Socinski M" first="Mark A" last="Socinski">Mark A. Socinski</name><affiliation wicri:level="2"><nlm:affiliation>University of Pittsburgh Medical Center, Pittsburgh, PA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Pennsylvanie</region></placeName><wicri:cityArea>University of Pittsburgh Medical Center, Pittsburgh</wicri:cityArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2015">2015</date><idno type="RBID">pubmed:25572008</idno><idno type="pmid">25572008</idno><idno type="doi">10.1016/j.cllc.2014.09.003</idno><idno type="wicri:Area/PubMed/Corpus">000496</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000496</idno><idno type="wicri:Area/PubMed/Curation">000496</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000496</idno><idno type="wicri:Area/PubMed/Checkpoint">000496</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000496</idno><idno type="wicri:Area/Ncbi/Merge">004684</idno><idno type="wicri:Area/Ncbi/Curation">004684</idno><idno type="wicri:Area/Ncbi/Checkpoint">004684</idno><idno type="wicri:Area/Main/Merge">000228</idno><idno type="wicri:Area/Main/Curation">000228</idno><idno type="wicri:Area/Main/Exploration">000228</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Weekly nab-paclitaxel in combination with carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: analysis of safety and efficacy in patients with renal impairment.</title><author><name sortKey="Langer, Corey J" sort="Langer, Corey J" uniqKey="Langer C" first="Corey J" last="Langer">Corey J. Langer</name><affiliation wicri:level="2"><nlm:affiliation>University of Pennsylvania, Perelman Center for Advanced Medicine, Abramson Cancer Center, Philadelphia, PA. Electronic address: corey.langer@uphs.upenn.edu.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Pennsylvanie</region></placeName><wicri:cityArea>University of Pennsylvania, Perelman Center for Advanced Medicine, Abramson Cancer Center, Philadelphia</wicri:cityArea></affiliation></author><author><name sortKey="Hirsh, Vera" sort="Hirsh, Vera" uniqKey="Hirsh V" first="Vera" last="Hirsh">Vera Hirsh</name><affiliation wicri:level="4"><nlm:affiliation>McGill University, Montreal, Quebec, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>McGill University, Montreal, Quebec</wicri:regionArea><orgName type="university">Université McGill</orgName><placeName><settlement type="city">Montréal</settlement><region type="state">Québec</region></placeName></affiliation></author><author><name sortKey="Ko, Amy" sort="Ko, Amy" uniqKey="Ko A" first="Amy" last="Ko">Amy Ko</name><affiliation wicri:level="2"><nlm:affiliation>Celgene Corporation, Summit, NJ.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">New Jersey</region></placeName><wicri:cityArea>Celgene Corporation, Summit</wicri:cityArea></affiliation></author><author><name sortKey="Renschler, Markus F" sort="Renschler, Markus F" uniqKey="Renschler M" first="Markus F" last="Renschler">Markus F. Renschler</name><affiliation wicri:level="2"><nlm:affiliation>Celgene Corporation, Summit, NJ.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">New Jersey</region></placeName><wicri:cityArea>Celgene Corporation, Summit</wicri:cityArea></affiliation></author><author><name sortKey="Socinski, Mark A" sort="Socinski, Mark A" uniqKey="Socinski M" first="Mark A" last="Socinski">Mark A. Socinski</name><affiliation wicri:level="2"><nlm:affiliation>University of Pittsburgh Medical Center, Pittsburgh, PA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Pennsylvanie</region></placeName><wicri:cityArea>University of Pittsburgh Medical Center, Pittsburgh</wicri:cityArea></affiliation></author></analytic><series><title level="j">Clinical lung cancer</title><idno type="eISSN">1938-0690</idno><imprint><date when="2015" type="published">2015</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Albumins (administration & dosage)</term><term>Antineoplastic Combined Chemotherapy Protocols (administration & dosage)</term><term>Antineoplastic Combined Chemotherapy Protocols (adverse effects)</term><term>Antineoplastic Combined Chemotherapy Protocols (therapeutic use)</term><term>Carboplatin (administration & dosage)</term><term>Carcinoma, Non-Small-Cell Lung (drug therapy)</term><term>Carcinoma, Non-Small-Cell Lung (pathology)</term><term>Disease-Free Survival</term><term>Female</term><term>Humans</term><term>Lung Neoplasms (drug therapy)</term><term>Lung Neoplasms (pathology)</term><term>Male</term><term>Middle Aged</term><term>Paclitaxel (administration & dosage)</term><term>Renal Insufficiency (complications)</term><term>Renal Insufficiency (physiopathology)</term><term>Survival Rate</term><term>Treatment Outcome</term><term>Young Adult</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Albumines (administration et posologie)</term><term>Carboplatine (administration et posologie)</term><term>Carcinome pulmonaire non à petites cellules (anatomopathologie)</term><term>Carcinome pulmonaire non à petites cellules (traitement médicamenteux)</term><term>Femelle</term><term>Humains</term><term>Insuffisance rénale ()</term><term>Insuffisance rénale (physiopathologie)</term><term>Jeune adulte</term><term>Mâle</term><term>Paclitaxel (administration et posologie)</term><term>Protocoles de polychimiothérapie antinéoplasique (administration et posologie)</term><term>Protocoles de polychimiothérapie antinéoplasique (effets indésirables)</term><term>Protocoles de polychimiothérapie antinéoplasique (usage thérapeutique)</term><term>Résultat thérapeutique</term><term>Sujet âgé</term><term>Sujet âgé de 80 ans ou plus</term><term>Survie sans rechute</term><term>Taux de survie</term><term>Tumeurs du poumon (anatomopathologie)</term><term>Tumeurs du poumon (traitement médicamenteux)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Albumins</term><term>Carboplatin</term><term>Paclitaxel</term></keywords><keywords scheme="MESH" qualifier="administration & dosage" xml:lang="en"><term>Antineoplastic Combined Chemotherapy Protocols</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Albumines</term><term>Carboplatine</term><term>Paclitaxel</term><term>Protocoles de polychimiothérapie antinéoplasique</term></keywords><keywords scheme="MESH" qualifier="adverse effects" xml:lang="en"><term>Antineoplastic Combined Chemotherapy Protocols</term></keywords><keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Carcinome pulmonaire non à petites cellules</term><term>Tumeurs du poumon</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Renal Insufficiency</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Carcinoma, Non-Small-Cell Lung</term><term>Lung Neoplasms</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Protocoles de polychimiothérapie antinéoplasique</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Carcinoma, Non-Small-Cell Lung</term><term>Lung Neoplasms</term></keywords><keywords scheme="MESH" qualifier="physiopathologie" xml:lang="fr"><term>Insuffisance rénale</term></keywords><keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Renal Insufficiency</term></keywords><keywords scheme="MESH" qualifier="therapeutic use" xml:lang="en"><term>Antineoplastic Combined Chemotherapy Protocols</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Carcinome pulmonaire non à petites cellules</term><term>Tumeurs du poumon</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Protocoles de polychimiothérapie antinéoplasique</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Disease-Free Survival</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Survival Rate</term><term>Treatment Outcome</term><term>Young Adult</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Femelle</term><term>Humains</term><term>Insuffisance rénale</term><term>Jeune adulte</term><term>Mâle</term><term>Résultat thérapeutique</term><term>Sujet âgé</term><term>Sujet âgé de 80 ans ou plus</term><term>Survie sans rechute</term><term>Taux de survie</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Renal impairment in cancer patients can affect treatment tolerability and outcomes. This analysis evaluated the safety and efficacy of nab-paclitaxel (nab-P) versus solvent-based paclitaxel (sb-P), both in combination with carboplatin (C), in patients with advanced non-small-cell lung cancer (NSCLC) and renal impairment.</div></front></TEI><affiliations><list><country><li>Canada</li><li>États-Unis</li></country><region><li>New Jersey</li><li>Pennsylvanie</li><li>Québec</li></region><settlement><li>Montréal</li></settlement><orgName><li>Université McGill</li></orgName></list><tree><country name="États-Unis"><region name="Pennsylvanie"><name sortKey="Langer, Corey J" sort="Langer, Corey J" uniqKey="Langer C" first="Corey J" last="Langer">Corey J. Langer</name></region><name sortKey="Ko, Amy" sort="Ko, Amy" uniqKey="Ko A" first="Amy" last="Ko">Amy Ko</name><name sortKey="Renschler, Markus F" sort="Renschler, Markus F" uniqKey="Renschler M" first="Markus F" last="Renschler">Markus F. Renschler</name><name sortKey="Socinski, Mark A" sort="Socinski, Mark A" uniqKey="Socinski M" first="Mark A" last="Socinski">Mark A. Socinski</name></country><country name="Canada"><region name="Québec"><name sortKey="Hirsh, Vera" sort="Hirsh, Vera" uniqKey="Hirsh V" first="Vera" last="Hirsh">Vera Hirsh</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Amérique/explor/PittsburghV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000228 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000228 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Amérique
|area= PittsburghV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:25572008
|texte= Weekly nab-paclitaxel in combination with carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: analysis of safety and efficacy in patients with renal impairment.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:25572008" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a PittsburghV1
| This area was generated with Dilib version V0.6.38. |  |